Evaluating quality of life in esophageal cancer patients after chemoradiation
Official title: Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant or Definitive Chemoradiation in Patients With Esophageal Cancer
Run by Ludwig-Maximilians - University of Munich · NCT03712774 · Data updated 2026-11-12
This study is trying to see how treatment with chemoradiation affects the quality of life for people with esophageal cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Ludwig-Maximilians - University of Munich Academic / other |
| Locations | 1 site (Munich, Bavaria) |
| Status | Recruiting |
| Started | October 12, 2018 |
| Main results expected | December 31, 2021 |
| Study ends | December 31, 2026 |
| Registry record updated | October 19, 2018 |
| Trial ID | NCT03712774 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with histologically proven esophageal cancer who are eligible for neoadjuvant or definitive chemoradiation.
✕Probably not a fit
Patients with distant metastases (except supraclavicular nodes), those receiving palliative treatment, or individuals with prior systemic treatment for esophageal cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the quality of life in patients with esophageal cancer who are undergoing neoadjuvant or definitive chemoradiation. Quality of life will be measured using standardized EORTC questionnaires, while also evaluating acute and late toxicities, functional outcomes, and oncological results. The study will track local and distant control, freedom from treatment failure, and overall survival, with planned correlations between patient and physician assessments of functional outcomes.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the quality of life and treatment outcomes for patients with esophageal cancer undergoing chemoradiation.
How similar studies have gone: While this approach is observational, similar studies evaluating quality of life in cancer patients have shown promising results, indicating the potential for meaningful insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * histologically proven esophageal Cancer (SCC or adenocarcinoma) without distant metastases (except supraclavicular nodes) * indication for neoadjuvant or definitive chemoradiation using either cisplatin/5-FU or carboplatin/paclitaxel with curative intent * age \>= 18 years * written informed consent * ability to answer the standardized questionaires according to the treating physician Exclusion Criteria: * age \< 18 years * Treatment with palliative intent * distant metastases (except supraclavicular nodes) * second malignancy * Prior systemic treatment for esophageal Cancer * Treatment in an interventional study
Where it's running
-
Department of Radiation Oncology, University Hospital, LMU Munich
Munich, Bavaria, Germany Recruiting
Study contacts
- Principal investigator: Falk Roeder, MD — Ludwig-Maximilians Universität München
- Study coordinator: Falk Roeder, MD
- Email: Falk.Roeder@t-online.de
- Phone: +49 89 4400
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Impact of Chemoradiation on Pneumococcal Vaccine Response in Esophageal Cancer Patients
This study is testing how radiation treatment affects the immune response to a pneumonia vaccine in patients with esophageal cancer who have low white blood cell counts after their treatment.
-
Neoadjuvant treatments for esophageal cancer
This study is testing different combinations of treatments for people with esophageal cancer to see if they can improve outcomes compared to just having surgery.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.
-
MGC030 in adults with advanced solid tumors
This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.